Sutro Biopharma (STRO) Cash from Investing Activities (2017 - 2025)

Sutro Biopharma's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $18.7 million for Q4 2025.

• In Q4 2025, Cash from Investing Activities fell 78.62% year-over-year to $18.7 million; the TTM figure through Dec 2025 stood at $45.0 million (down 79.4% YoY), while the FY2025 annual figure was $45.0 million, down 79.4% from the prior year.
• Cash from Investing Activities came in at $18.7 million for Q4 2025 at Sutro Biopharma, down from $40.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $147.3 million in Q3 2024 to a low of -$121.7 million in Q1 2021.
• A 5-year average of $6.4 million and a median of $12.3 million in 2021 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 715.44% in 2022 and fell as far as 3380.69% in 2022.
• Sutro Biopharma's Cash from Investing Activities stood at $20.8 million in 2021, then sank by 282.29% to -$37.9 million in 2022, then soared by 37.93% to -$23.5 million in 2023, then soared by 472.08% to $87.5 million in 2024, then sank by 78.62% to $18.7 million in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $18.7 million, $40.0 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison